News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: Boehringer Ingelheim Corporation to Build Biopharma CMO in Shanghai


6/10/2013 9:16:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 8, 2013 -- Boehringer Ingelheim will build a cGMP CMO facility in Shanghai’s Zhangjiang Hi-Tech Park in cooperation with Zhangjiang Biotech and Pharmaceutical Base Development Co. and funded with an $81 million joint investment; the China Securities Regulatory Commission terminated the IPO applications of fifteen China life science companies; Janssen Pharma and the National Taiwan University Hospital will co-develop new drugs for hepatitis B; Genor Biopharma of Shanghai has agreed with BioCND, a Korean biosimilar CRO, to co-develop biosimilars of Humira and Herceptin; China’s Center for Disease Control and Prevention will team up with The Center for Infection and Immunity (CII) of Columbia University to form a Pathogen Discovery lab, housed in China’s CDCP; AngioLight, a cardiovascular medical device company located in Massachusetts, completed a successful initial animal study of its AngioLight™ System at Fu Wai Hospital in Beijing; and more than 750 forward-thinking industry executives converged upon Beijing last week for the ChinaBio® Partnering Forum, China’s premier life science partnering event. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES